Anti-Human CD52 (Alemtuzumab) – Dylight® 488

Anti-Human CD52 (Alemtuzumab) – Dylight® 488

Product No.: LT211

- -
- -
Product No.LT211
Clone
Campath-1H
Target
CD52
Product Type
Biosimilar Recombinant Human Monoclonal Antibody
Alternate Names
HE5; CDW52; EDDM5 CDW52; Cambridge pathology 1 antigen
Isotype
Human IgG1κ
Applications
FA
,
FC
,
IHC FF
,
IHC FFPE

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human/Rhesus Monkey/Cynomolgus Monkey
Expression Host
HEK-293 Cells
FC Effector Activity
Active
Immunogen
Human lymphocytes.
Product Concentration
0.2 mg/ml
Formulation
This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage and Handling
This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze.
Regulatory Status
Research Use Only (RUO). Non-Therapeutic.
Country of Origin
USA
Shipping
Next Day 2-8°C
Excitation Laser
Blue Laser (493 nm)
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for Alemtuzumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Additional Applications Reported In Literature ?
IHC FFPE (Formalin-fixed paraffin-embedded tissue)
IHC FF (Fresh Frozen)
FA
Additional Reported Applications For Relevant Conjugates ?
CyTOF®
WB
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Alemtuzumab. Clone Campath-1H recognizes human CD52. This product is for research use only.
Background
Clone Campath-1H is a monoclonal antibody that specifically binds to CD52, a protein present on the surface of mature lymphocytes. However, this protein is not present on the stem cells that generated these lymphocytes. Alemtuzumab is targets and destroys mature lymphocytes containing CD-52, and is used to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis. Anti-Human CD52 (Alemtuzumab) utilizes the same variable regions from the therapeutic antibody Alemtuzumab making it ideal for research projects.
Antigen Distribution
CD52 is primarily expressed on the surface of mature lymphocytes. Additionally, CD52 is present on most lymphoid derived malignancies. However, variable expression on Myeloma cells should be noted.

Antigen Details

PubMed
NCBI Gene Bank ID
FA
Flow Cytometry
IHC FF
IHC FFPE

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.